EDELRIS

Edelris is a drug discovery contract research organization (CRO) founded in 2005 and based in Lyon, France. The company provides a comprehensive suite of services including medicinal chemistry, high-throughput screening, and the provision of diverse, lead-like compound libraries, such as its proprietary Keymical Space collection. Edelris leverages advanced technologies including mass spectrometry-based screening, parallel synthesis, flow chemistry, and computational methods to assist clients in identifying and optimizing drug candidates. Its scientific team, composed largely of Ph.D.-level experts, supports partners in sectors ranging from pharmaceutical and biotech to cosmetic and crop protection by tackling complex targets, including those involved in targeted protein degradation.

These capabilities allow Edelris to help partners accelerate small molecule drug discovery programs from hit identification through lead optimization. The company has a proven track record of successfully progressing medicinal chemistry projects for major industry players, such as Pfizer and Bayer, as well as academic and research institutions. By providing both specialized infrastructure and deep chemical expertise, Edelris enables its clients to navigate the early phases of drug development more efficiently, addressing challenges such as hit exploration, structure-activity relationship (SAR) analysis, and the selection of preclinical candidates for further therapeutic development.